{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:05:25Z","timestamp":1772107525989,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40256-020-00459-1","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:02:37Z","timestamp":1609153357000},"page":"499-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes"],"prefix":"10.1007","volume":"21","author":[{"given":"Subuhi","family":"Kaul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasvi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhrubajyoti","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrija","family":"Hajra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamas","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-3488","authenticated-orcid":false,"given":"Raktim K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"459_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039\u201352.","journal-title":"Lancet"},{"key":"459_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-020-02175-2","volume":"22","author":"LD Colantonio","year":"2020","unstructured":"Colantonio LD, Saag KG, Singh JA, et al. Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. Arthritis Res Ther. 2020;22:86.","journal-title":"Arthritis Res Ther"},{"key":"459_CR3","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/ar3684","volume":"14","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O. Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther. 2012;14:R10.","journal-title":"Arthritis Res Ther"},{"key":"459_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/HJH.0000000000002287","volume":"38","author":"E Casiglia","year":"2020","unstructured":"Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: the URRAH (Uric Acid Right for Heart Health) study. J Hypertens. 2020;38:412\u20139.","journal-title":"J Hypertens"},{"key":"459_CR5","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505.","journal-title":"N Engl J Med"},{"key":"459_CR6","doi-asserted-by":"crossref","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447\u20131461.","DOI":"10.1002\/acr.21773"},{"key":"459_CR7","doi-asserted-by":"crossref","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431\u20131446.","DOI":"10.1002\/acr.21772"},{"key":"459_CR8","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685\u201395.","journal-title":"N Engl J Med"},{"key":"459_CR9","doi-asserted-by":"crossref","unstructured":"Libby P, Ridker PM, Hansson GK, Leducq transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129\u20132138.","DOI":"10.1016\/j.jacc.2009.09.009"},{"key":"459_CR10","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, et al. ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921\u201364.","journal-title":"Eur Heart J"},{"key":"459_CR11","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/heartjnl-2015-309211","volume":"102","author":"DC Tong","year":"2016","unstructured":"Tong DC, Wilson AM, Layland J. Colchicine in cardiovascular disease: an ancient drug with modern tricks. Heart. 2016;102:995\u20131002.","journal-title":"Heart"},{"key":"459_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","volume":"11","author":"K Vaidya","year":"2018","unstructured":"Vaidya K, Arnott C, Mart\u00ednez GJ, et al. Colchicine therapy and plaque stabilization in patients with acute\u00a0coronary syndrome: a CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11:305\u201316.","journal-title":"JACC Cardiovasc Imaging"},{"key":"459_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","volume":"215","author":"T Hennessy","year":"2019","unstructured":"Hennessy T, Soh L, Bowman M, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:62\u20139.","journal-title":"Am Heart J"},{"key":"459_CR14","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","volume":"61","author":"S Deftereos","year":"2013","unstructured":"Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61:1679\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"459_CR15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","volume":"132","author":"S Deftereos","year":"2015","unstructured":"Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015;132:1395\u2013403.","journal-title":"Circulation"},{"key":"459_CR16","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.clinthera.2019.07.015","volume":"41","author":"B Tucker","year":"2019","unstructured":"Tucker B, Kurup R, Barraclough J, et al. Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study. Clin Ther. 2019;41:2172\u201381.","journal-title":"Clin Ther"},{"key":"459_CR17","doi-asserted-by":"publisher","first-page":"e008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","volume":"13","author":"B Shah","year":"2020","unstructured":"Shah B, Pillinger M, Zhong H, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. 2020;13:e008717.","journal-title":"Circ Cardiovasc Interv"},{"key":"459_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"459_CR19","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347.","journal-title":"N Engl J Med"},{"key":"459_CR20","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","volume":"75","author":"DH Solomon","year":"2016","unstructured":"Solomon DH, Liu C-C, Kuo I-H, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75:1674\u20139.","journal-title":"Ann Rheum Dis"},{"key":"459_CR21","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.111533","volume":"39","author":"DB Crittenden","year":"2012","unstructured":"Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39:1458\u201364.","journal-title":"J Rheumatol"},{"key":"459_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clinthera.2018.08.008","volume":"41","author":"SG Deftereos","year":"2019","unstructured":"Deftereos SG, Vrachatis DA, Angelidis C, et al. The role of colchicine in treating postoperative and post-catheter ablation atrial fibrillation. Clin Ther. 2019;41:21\u20139.","journal-title":"Clin Ther"},{"key":"459_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijcard.2017.08.039","volume":"249","author":"C Lennerz","year":"2017","unstructured":"Lennerz C, Barman M, Tantawy M, Sopher M, Whittaker P. Colchicine for primary prevention of atrial fibrillation after open-heart surgery: systematic review and meta-analysis. Int J Cardiol. 2017;249:127\u201337.","journal-title":"Int J Cardiol"},{"key":"459_CR24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.2014.11026","volume":"312","author":"M Imazio","year":"2014","unstructured":"Imazio M, Brucato A, Ferrazzi P, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016\u201323.","journal-title":"JAMA"},{"key":"459_CR25","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/eurheartj\/ehq319","volume":"31","author":"M Imazio","year":"2010","unstructured":"Imazio M, Trinchero R, Brucato A, et al. COlchicine for the prevention of the post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31:2749\u201354.","journal-title":"Eur Heart J"},{"key":"459_CR26","unstructured":"NIH US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322682. Accessed 12 Dec 2020."},{"key":"459_CR27","doi-asserted-by":"publisher","unstructured":"Papadopoulos C, Patoulias D, Teperikidis E, et al. Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review. SN Compr Clin Med. Epub 4 Aug 2020. https:\/\/doi.org\/10.1007\/s42399-020-00421-x.","DOI":"10.1007\/s42399-020-00421-x"},{"key":"459_CR28","doi-asserted-by":"publisher","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","volume":"3","author":"SG Deftereos","year":"2020","unstructured":"Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3:e2013136.","journal-title":"JAMA Netw Open"},{"key":"459_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF02172087","volume":"3","author":"C Grunfeld","year":"1991","unstructured":"Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 1991;3:143\u201358.","journal-title":"Biotherapy"},{"key":"459_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2012.09.066","volume":"61","author":"S Rekhraj","year":"2013","unstructured":"Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61:926\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"459_CR31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","volume":"74","author":"L Grimaldi-Bensouda","year":"2015","unstructured":"Grimaldi-Bensouda L, Alp\u00e9rovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74:836\u201342.","journal-title":"Ann Rheum Dis"},{"key":"459_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/heartjnl-2014-306670","volume":"101","author":"FJ de Abajo","year":"2015","unstructured":"de Abajo FJ, Gil MJ, Rodr\u00edguez A, et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015;101:679\u201385.","journal-title":"Heart"},{"issue":"299\u2013306","key":"459_CR33","first-page":"e2","volume":"129","author":"KS Larsen","year":"2016","unstructured":"Larsen KS, Potteg\u00e5rd A, Lindegaard HM, Hallas J. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. Am J Med. 2016;129(299\u2013306):e2.","journal-title":"Am J Med"},{"key":"459_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13075-016-1111-1","volume":"18","author":"JA Singh","year":"2016","unstructured":"Singh JA, Yu S. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Res Ther. 2016;18:209.","journal-title":"Arthritis Res Ther."},{"key":"459_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1751-7176.2012.00701.x","volume":"15","author":"V Agarwal","year":"2013","unstructured":"Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15:435\u201342.","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"459_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","volume":"18","author":"M Bredemeier","year":"2018","unstructured":"Bredemeier M, Lopes LM, Eisenreich MA, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18:24.","journal-title":"BMC Cardiovasc Disord."},{"key":"459_CR37","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","volume":"105","author":"W Doehner","year":"2002","unstructured":"Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619\u201324.","journal-title":"Circulation"},{"key":"459_CR38","doi-asserted-by":"publisher","first-page":"e013774","DOI":"10.1136\/bmjopen-2016-013774","volume":"6","author":"IS Mackenzie","year":"2016","unstructured":"Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016;6:e013774.","journal-title":"BMJ Open"},{"key":"459_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cbi.2015.05.013","volume":"237","author":"B Krishnamurthy","year":"2015","unstructured":"Krishnamurthy B, Rani N, Bharti S, et al. Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats. Chem Biol Interact. 2015;237:96\u2013103.","journal-title":"Chem Biol Interact"},{"key":"459_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12967-015-0578-x","volume":"13","author":"S Wang","year":"2015","unstructured":"Wang S, Li Y, Song X, et al. Febuxostat pretreatment attenuates myocardial ischemia\/reperfusion injury via mitochondrial apoptosis. J Transl Med. 2015;13:209.","journal-title":"J Transl Med."},{"key":"459_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ahj.2017.11.006","volume":"197","author":"AG Hays","year":"2018","unstructured":"Hays AG, Iantorno M, Sch\u00e4r M, et al. The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: a phase 4 randomized, placebo-controlled, double-blind, crossover trial. Am Heart J. 2018;197:85\u201393.","journal-title":"Am Heart J"},{"key":"459_CR42","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916\u201323.","journal-title":"Arthritis Rheum"},{"key":"459_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273\u201382.","journal-title":"J Rheumatol"},{"key":"459_CR44","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher","year":"2008","unstructured":"Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540\u20138.","journal-title":"Arthritis Rheum"},{"key":"459_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher","year":"2009","unstructured":"Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188\u201394.","journal-title":"Rheumatology (Oxford)"},{"key":"459_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200\u201310.","journal-title":"N Engl J Med"},{"key":"459_CR47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/acr2.11047","volume":"1","author":"AM Abeles","year":"2019","unstructured":"Abeles AM, Pillinger MH. Febuxostat and the black box blues. ACR Open Rheumatol. 2019;1:343\u20134.","journal-title":"ACR Open Rheumatol"},{"key":"459_CR48","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/art.40583","volume":"70","author":"H Choi","year":"2018","unstructured":"Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated food and drug administration public safety alert. Arthritis Rheumatol. 2018;70:1702\u20139.","journal-title":"Arthritis Rheumatol."},{"issue":"10264","key":"459_CR49","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM. FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020 Nov 28;396(10264):1745\u201357.","journal-title":"Lancet."},{"issue":"9","key":"459_CR50","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/rheumatology\/kez576","volume":"59","author":"C Ju","year":"2020","unstructured":"Ju C, Lai RWC, Li KHC, et al. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology (Oxford). 2020;59(9):2340\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"459_CR51","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1536\/ihj.17-560","volume":"59","author":"T Yokota","year":"2018","unstructured":"Yokota T, Fukushima A, Kinugawa S, Okumura T, Murohara T, Tsutsui H. Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF). Int Heart J. 2018;59:976\u201382.","journal-title":"Int Heart J"},{"key":"459_CR52","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","volume":"138","author":"M Zhang","year":"2018","unstructured":"Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study. Circulation. 2018;138:1116\u201326.","journal-title":"Circulation"},{"key":"459_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cpt.1377","volume":"106","author":"C-H Chen","year":"2019","unstructured":"Chen C-H, Chen C-B, Chang CJ, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population-based cohort study and meta-analysis. Clin Pharmacol Ther. 2019;106:391\u2013401.","journal-title":"Clin Pharmacol Ther"},{"key":"459_CR54","doi-asserted-by":"publisher","first-page":"e1003095","DOI":"10.1371\/journal.pmed.1003095","volume":"17","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Taguchi I, Teragawa H, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial. PLoS Med. 2020;17:e1003095.","journal-title":"PLoS Med."},{"key":"459_CR55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14740338.2019.1594771","volume":"18","author":"L Strilchuk","year":"2019","unstructured":"Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf. 2019;18:261\u201371.","journal-title":"Expert Opin Drug Saf"},{"key":"459_CR56","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/clc.22988","volume":"41","author":"BW Van Tassell","year":"2018","unstructured":"Van Tassell BW, Lipinski MJ, Appleton D, et al. Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study. Clin Cardiol. 2018;41:1004\u20138.","journal-title":"Clin Cardiol"},{"key":"459_CR57","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"J Poiley","year":"2016","unstructured":"Poiley J, Steinberg AS, Choi Y-J, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatology. 2016;68:2027\u201334.","journal-title":"Arthritis Rheumatology."},{"key":"459_CR58","doi-asserted-by":"publisher","first-page":"e18245","DOI":"10.1097\/MD.0000000000018245","volume":"98","author":"C-Y Zou","year":"2019","unstructured":"Zou C-Y, Liu X-K, Sang Y-Q, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine (Baltimore). 2019;98:e18245.","journal-title":"Medicine (Baltimore)"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00459-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00459-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:08:59Z","timestamp":1744715339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00459-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00459-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,28]]},"assertion":[{"value":"17 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Fonarow discloses the following relationships: consultant for Abbott, Amgen, AstraZeneca, Bayer, Janssen, Medtronic, Merck, and Novartis, and Associate Section Editor for the Journal of the American Medical Association (JAMA) Cardiology. Subuhi Kaul, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Adrija Hajra, Prakash Deedwania, Edward Roddy, Mamas Mamas, Allan Klein, Carl J. Lavie, and Raktim K. Ghosh have no disclosures to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No sources of funding were used to assist in the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}